1. Home
  2. LLY vs AZN Comparison

LLY vs AZN Comparison

Compare LLY & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eli Lilly and Company

LLY

Eli Lilly and Company

HOLD

Current Price

$1,255.48

Market Cap

979.6B

Sector

Health Care

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$166.22

Market Cap

316.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LLY
AZN
Founded
1876
1992
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
979.6B
316.4B
IPO Year
2007
1995

Fundamental Metrics

Financial Performance
Metric
LLY
AZN
Price
$1,255.48
$166.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
1
Target Price
$1,218.84
N/A
AVG Volume (30 Days)
2.1M
4.0M
Earning Date
04-30-2026
04-29-2026
Dividend Yield
0.81%
1.73%
EPS Growth
95.99
N/A
EPS
16.19
N/A
Revenue
$65,179,000,000.00
N/A
Revenue This Year
$27.15
$10.34
Revenue Next Year
$16.04
$6.43
P/E Ratio
$77.04
$31.91
Revenue Growth
44.70
N/A
52 Week Low
$694.23
$72.90
52 Week High
$1,292.65
$212.71

Technical Indicators

Market Signals
Indicator
LLY
AZN
Relative Strength Index (RSI) 59.82 51.30
Support Level $978.43 $164.06
Resistance Level N/A $175.04
Average True Range (ATR) 40.91 2.73
MACD 6.59 1.24
Stochastic Oscillator 80.93 90.40

Price Performance

Historical Comparison
LLY
AZN

About LLY Eli Lilly and Company

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: